Drug Development Pharma - December 3, 2013
CMC Contrast granted orphan drug designation
The US Food and Drug Administration, FDA, has granted orphan drug designation for the company’s liver specific contrast agent CMC-001. The Orphan Drug Designation has been granted for CMC-001 for use as a targeted contrast agent for diagnostic MRI for detection and localization of focal liver lesions in patients where gadolinium-based contrast agents are contraindicated […]
